Morgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $98
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $94 to $98.
Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $94 to $98.